Metformin Hydrochloride Milpharm

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Milpharm, is a biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control.

GNH USA supplies Metformin Hydrochloride Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is a biguanide that lowers blood glucose in disorders of glucose metabolism. - Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels. - Impaired glucose tolerance (prediabetes): helps normalise fasting and post‑prandial glucose. - Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity.

Metformin Hydrochloride is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhoea: often mild to moderate and transient. - Metallic taste: a transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Vitamin B12 deficiency: may develop with long‑term therapy. - Hepatotoxicity: rare liver enzyme elevations.

Metformin Hydrochloride requires careful patient assessment and monitoring. - Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Alcohol consumption: limit intake to reduce acidosis risk. - Monitoring: check HbA1c and renal function regularly during therapy. - Pregnancy and lactation: assess risk‑benefit; generally avoided unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure. - Cimetidine: can increase metformin plasma concentrations. - Nitrates: combined use may raise the risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: require monitoring of renal function and electrolytes.